Comparison of Data from Two Commercially Available Tissue-Based Comprehensive Genomic Profiling (CGP) Solutions Using AMP/ASCO/CAP Guidelines and ESMO ESCAT

We compared theoretical clinical significance data from two CGP solutions – the AVENIO Tumor Tissue CGP Kit (for Research Use Only) paired with navify Mutation Profiler (NMP), and TruSight Oncology 500 (TSO) assay paired with PierianDx Clinical Genomics Workspace.

AVENIO and TSO assays were run on 145 FFPE solid tumour samples (prostate: n=28; breast: 27; colon: 26; lung: 25 [among others]). Variant calls were acquired using manufacturer-provided software. Key variant annotation outputs were variant tiers and ESCAT guideline inclusion per tumor type. AMP/ASCO/CAP tiers were obtained with NMP for AVENIO or PierianDx for TSO. ESCAT inclusion was determined manually.